Pamela Cristina Lukasewicz Ferreira

Pamela Cristina Lukasewicz Ferreira

Auto-generated profile, based on publicly available information

Pamela Cristina Lukasewicz Ferreira

Department of Psychiatry, School of Medicine, University of Pittsburgh, PA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
BBBruna Bellaver
Bruna Bellaver
GPGuilherme Povala
Guilherme Povala
PFPamela C. L. Ferreira
Pamela C. L. Ferreira
JFJoão Pedro Ferrari-Souza
João Pedro Ferrari-Souza
DLDouglas T. Leffa
Douglas T. Leffa
TPTharick A. Pascoal
Tharick A. Pascoal
An unresolved question for the understanding of Alzheimer’s disease (AD) pathophysiology is why a significant percentage of amyloid-β (Aβ)-positive cognitively unimpaired (CU) individuals do not develop detectable downstream tau pathology and, consequently, clinical deterioration. In vitro evidence suggests that reactive astrocytes unleash Aβ effects in pathological tau phosphorylation. Here, in a biomarker study across three cohorts (n = 1,016), we tested whether astrocyte reactivity modulates the association of Aβ with tau phosphorylation in CU individuals. We found that Aβ was associated with increased plasma phosphorylated tau only in individuals positive for astrocyte reactivity (Ast+). Cross-sectional and longitudinal tau–positron emission tomography analyses revealed an AD-like pattern of tau tangle accumulation as a function of Aβ only in CU Ast+individuals. Our findings suggest astrocyte reactivity as an important upstream event linking Aβ with initial tau pathology, which may have implications for the biological definition of preclinical AD and for selecting CU individuals for clinical trials.

7 April 2023 in Science Advances
Verified
Journal Article
Open access
JFJoão Pedro Ferrari-Souza
João Pedro Ferrari-Souza
FLFiroza Z. Lussier
Firoza Z. Lussier
DLDouglas T. Leffa
Douglas T. Leffa
JTJoseph Therriault
Joseph Therriault
CTCécile Tissot
Cécile Tissot
TPTharick A. Pascoal
Tharick A. Pascoal
Animal studies suggest that the apolipoprotein E ε4 ( APOE ε4) allele is a culprit of early microglial activation in Alzheimer’s disease (AD). Here, we tested the association between APOE ε4 status and microglial activation in living individuals across the aging and AD spectrum. We studied 118 individuals with positron emission tomography for amyloid-β (Aβ; [ 18 F]AZD4694), tau ([ 18 F]MK6240), and microglial activation ([ 11 C]PBR28). We found that APOE ε4 carriers presented increased microglial activation relative to noncarriers in early Braak stage regions within the medial temporal cortex accounting for Aβ and tau deposition. Furthermore, microglial activation mediated the Aβ-independent effects of APOE ε4 on tau accumulation, which was further associated with neurodegeneration and clinical impairment. The physiological distribution of APOE mRNA expression predicted the patterns of APOE ε4-related microglial activation in our population, suggesting that APOE gene expression may regulate the local vulnerability to neuroinflammation. Our results support that the APOE ε4 genotype exerts Aβ-independent effects on AD pathogenesis by activating microglia in brain regions associated with early tau deposition.

6 March 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
PFPamela C. L. Ferreira
Pamela C. L. Ferreira
YZYingjin Zhang
Yingjin Zhang
BSBeth Snitz
Beth Snitz
CCChung‐Chou H. Chang
Chung‐Chou H. Chang
BBBruna Bellaver
Bruna Bellaver
TKThomas K. Karikari
Thomas K. Karikari
Introduction: Plasma biomarkers—cost effective, non‐invasive indicators of Alzheimer's disease (AD) and related disorders (ADRD)—have largely been studied in clinical research settings. Here, we examined plasma biomarker profiles and their associated factors in a population‐based cohort to determine whether they could identify an at‐risk group, independently of brain and cerebrospinal fluid biomarkers.Methods: We measured plasma phosphorylated tau181 (p‐tau181), neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and amyloid beta (Aβ)42/40 ratio in 847 participants from a population‐based cohort in southwestern Pennsylvania.Results: K‐medoids clustering identified two distinct plasma Aβ42/40 modes, further categorizable into three biomarker profile groups: normal, uncertain, and abnormal. In different groups, plasma p‐tau181, NfL, and GFAP were inversely correlated with Aβ42/40, Clinical Dementia Rating, and memory composite score, with the strongest associations in the abnormal group.Discussion: Abnormal plasma Aβ42/40 ratio identified older adult groups with lower memory scores, higher dementia risks, and higher ADRD biomarker levels, with potential implications for population screening.Highlights: Population‐based plasma biomarker studies are lacking, particularly in cohorts without cerebrospinal fluid or neuroimaging data. In the Monongahela‐Youghiogheny Healthy Aging Team study (n = 847), plasma biomarkers associated with worse memory and Clinical Dementia Rating (CDR), apolipoprotein E ε4, and greater age. Plasma amyloid beta (Aβ)42/40 ratio levels allowed clustering participants into abnormal, uncertain, and normal groups. Plasma Aβ42/40 correlated differently with neurofilament light chain, glial fibrillary acidic protein, phosphorylated tau181, memory composite, and CDR in each group. Plasma biomarkers can enable relatively affordable and non‐invasive community screening for evidence of Alzheimer's disease and related disorders pathophysiology.

6 November 2025 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
JFJoão Pedro Ferrari-Souza
João Pedro Ferrari-Souza
GPGuilherme Povala
Guilherme Povala
NRNesrine Rahmouni
Nesrine Rahmouni
BBBruna Bellaver
Bruna Bellaver
PFPamela C. L. Ferreira
Pamela C. L. Ferreira
EZEduardo Zimmer
Eduardo Zimmer
Experimental evidence suggests that activated microglia induce astrocyte reactivity in neurodegenerative disorders, such as Alzheimer’s disease (AD). In this study, we investigated the association between microglial activation and amyloid-β (Aβ) with reactive astrogliosis in individuals across the AD spectrum. We examined 101 individuals using positron emission tomography radiotracers to assess Aβ deposition ([18F]AZD4694), tau aggregation ([18F]MK-6240) and microglial activation ([11C]PBR28), along with plasma biomarkers for astrocyte reactivity (GFAP) and tau phosphorylation (p-tau217). We further evaluated 251 individuals with cerebrospinal fluid levels of the microglial marker sTREM2. We found that Aβ pathology was associated with astrocyte reactivity across cortical brain regions only in the presence of microglial activation. The microglia-dependent effects of Aβ on astrocyte reactivity were further related to cognitive impairment through tau phosphorylation and aggregation. Our results suggest that microglial activation plays a key role in Aβ-related astrocyte reactivity, which, in turn, contributes to downstream pathological features of AD.

25 September 2023 in Nature Aging
Verified
Journal Article
Closed access
PDF file
JFJoão Pedro Ferrari-Souza
João Pedro Ferrari-Souza
BBBruna Bellaver
Bruna Bellaver
PFPâmela C. L. Ferreira
Pâmela C. L. Ferreira
ABAndréa L. Benedet
Andréa L. Benedet
GPGuilherme Povala
Guilherme Povala
TPTharick A. Pascoal
Tharick A. Pascoal

2 June 2020 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
PFPâmela C. Lukasewicz Ferreira
Pâmela C. Lukasewicz Ferreira
FTFlavia Valladao Thiesen
Flavia Valladao Thiesen
APAndrea Garcia Pereira
Andrea Garcia Pereira
AZAline Rigon Zimmer
Aline Rigon Zimmer
PFPedro Eduardo Fröehlich
Pedro Eduardo Fröehlich